{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:41:59Z","timestamp":1777927319102,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["TMC11RSV4001"],"award-info":[{"award-number":["TMC11RSV4001"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Darunavir (DRV) is approved for once-daily use in patients with no DRV resistance-associated mutations (RAMs) and twice-daily use in those with DRV RAMs. Several studies suggest that once-daily DRV retains efficacy in the setting of 1\u20132 DRV RAMs whereas three or more DRV RAMs are needed for DRV resistance. There are few data to support the long-term use of once-daily DRV in patients with DRV RAMs. This observational study evaluated 48-week clinical outcomes of 22 treatment-experienced patients with \u22651 DRV RAMs switched to once-daily DRV between 2014 and 2017. The primary endpoint was HIV-1 RNA &lt;50 copies\/ml at week 48. Safety parameters were analyzed throughout the study. The median age of the sample was 53\u2009years, 18 (82%) had baseline HIV-1 RNA &lt;50\u00a0copies\/ml, and the median number of historical DRV RAMs was 2. At week 48, 20 (91%) had HIV-1 RNA &lt;\u200950\u00a0copies\/ml, and 2 (9%) had HIV-1 RNA of 82 and 59,637\u00a0copies\/ml and reported non-adherence. No adverse drug reactions were observed through week 48. Once-daily DRV maintained virologic control in patients with \u22651 historical DRV RAMs and was safe and well-tolerated. Further data are needed to validate this as a viable treatment option in this population.<\/jats:p>","DOI":"10.1177\/0956462420926405","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T03:06:17Z","timestamp":1595473577000},"page":"958-966","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-2225","authenticated-orcid":false,"given":"Charlotte-Paige","family":"Rolle","sequence":"first","affiliation":[{"name":"Orlando Immunology Center, Orlando FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Marquez","sequence":"additional","affiliation":[{"name":"Emory University Rollins School of Public Health, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vu","family":"Nguyen","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Central Florida, Orlando, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Hinestrosa","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Central Florida, Orlando, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Central Florida, Orlando, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"bibr1-0956462420926405","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2569"},{"key":"bibr2-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12024"},{"key":"bibr3-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2017.1387690"},{"key":"bibr4-0956462420926405","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1472-8206.2011.00949.x","volume":"26","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"bibr5-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2007.0173"},{"key":"bibr6-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku131"},{"key":"bibr7-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.02.010"},{"key":"bibr8-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1086\/630210"},{"key":"bibr9-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001193"},{"key":"bibr10-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-018-0204-0"},{"key":"bibr11-0956462420926405","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services, http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf (accessed 10 August 2019)."},{"key":"bibr12-0956462420926405","unstructured":"S De Meyer, S Spinosa-Guzman, T Vangeneugdeet\u00a0al. Efficacy of PREZISTA\/r 800\/100\u00a0mg qd in patients with low resistance to PREZISTA. In: Poster presented at 5th European HIV Drug Resistance Workshop (EHDRW), Poster 48, Cascais, Portugal, 28\u201330 March 2007."},{"key":"bibr13-0956462420926405","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3319"},{"key":"bibr14-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2227"},{"key":"bibr15-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13081"},{"key":"bibr16-0956462420926405","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf (2017, accessed 12 February 2020)."},{"key":"bibr17-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60497-8"},{"key":"bibr18-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318183a959"},{"key":"bibr19-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2018.0100"},{"key":"bibr20-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx055"},{"key":"bibr21-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01747-10"},{"key":"bibr22-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx108"},{"key":"bibr23-0956462420926405","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3051"},{"key":"bibr24-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ193"},{"key":"bibr25-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1310\/hct1305-256"},{"key":"bibr26-0956462420926405","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12530"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462420926405","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0956462420926405","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462420926405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:40:46Z","timestamp":1777675246000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0956462420926405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1177\/0956462420926405"],"URL":"https:\/\/doi.org\/10.1177\/0956462420926405","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]}}}